↓ Skip to main content

Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study

Overview of attention for article published in Arthritis Research & Therapy, March 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
45 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study
Published in
Arthritis Research & Therapy, March 2015
DOI 10.1186/s13075-015-0571-z
Pubmed ID
Authors

Ariana Montes, Eva Perez-Pampin, Federico Navarro-Sarabia, Virginia Moreira, Arturo Rodríguez de la Serna, Berta Magallares, Yiannis Vasilopoulos, Theologia Sarafidou, Antonio Fernández-Nebro, María del Carmen Ordóñez, Javier Narváez, Juan D Cañete, Ana Marquez, Dora Pascual-Salcedo, Beatriz Joven, Patricia Carreira, Manuel J Moreno-Ramos, Rafael Caliz, Miguel Angel Ferrer, Rosa Garcia-Portales, Francisco J Blanco, Cesar Magro, Enrique Raya, Lara Valor, Juan J Alegre-Sancho, Alejandro Balsa, Javier Martin, Darren Plant, John Isaacs, Ann W Morgan, Anne Barton, Anthony G Wilson, on behalf of Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Juan J Gómez-Reino, Antonio Gonzalez

Abstract

We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthritis (RA). The G1m genotypes were analyzed in three collections of patients with RA totaling 1037 subjects. The first, used for discovery, comprised 215 Spanish patients. The second and third were successively used for replication. They included 429 British and Greek patients and 393 Spanish and British patients, respectively. Two outcomes were considered: change in the Disease Activity Score in 28 joint (ΔDAS28) and the European League Against Rheumatism (EULAR) response criteria. An association between less response to INX and incompatibility of the G1m1,17 allotype was found in the discovery collection at 6 months of treatment (P = 0.03). This association was confirmed in the replications (P = 0.02 and 0.08, respectively) leading to a global association (P = 0.001) that involved a mean difference in ΔDAS28 of 0.4 units between compatible and incompatible patients (2.3 ± 1.5 in compatible patients vs. 1.9 ± 1.5 in incompatible patients) and an increase in responders and decrease in non-responders according to the EULAR criteria (P = 0.03). A similar association was suggested for patients treated with ADM in the discovery collection, but it was not supported by replication. Our results suggest that G1m1,17 allotypes are associated with response to INX and could aid improved therapeutic targeting in RA.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Germany 1 2%
Unknown 43 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 18%
Student > Ph. D. Student 7 16%
Student > Master 6 13%
Professor 5 11%
Librarian 3 7%
Other 7 16%
Unknown 9 20%
Readers by discipline Count As %
Medicine and Dentistry 13 29%
Agricultural and Biological Sciences 9 20%
Biochemistry, Genetics and Molecular Biology 4 9%
Computer Science 2 4%
Business, Management and Accounting 1 2%
Other 5 11%
Unknown 11 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 April 2015.
All research outputs
#22,758,309
of 25,373,627 outputs
Outputs from Arthritis Research & Therapy
#3,132
of 3,381 outputs
Outputs of similar age
#250,758
of 291,325 outputs
Outputs of similar age from Arthritis Research & Therapy
#67
of 73 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,381 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,325 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 73 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.